Ignite Creation Date:
2024-05-06 @ 7:50 PM
Last Modification Date:
2024-10-26 @ 3:15 PM
Study NCT ID:
NCT06152731
Status:
RECRUITING
Last Update Posted:
2024-05-17
First Post:
2023-11-22
Brief Title:
HRD Tests for Ovarian cancER
Sponsor:
Centre Francois Baclesse
Organization:
Centre Francois Baclesse
Study Overview
Official Title:
HRD Tests for Ovarian cancER
Status:
RECRUITING
Status Verified Date:
2024-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
HERO
Brief Summary:
The study concerns patients with Invasive epithelial ovarian cancer primary Fallopian tube carcinoma ovarian-type peritoneal carcinoma and with an indication of a first-line platinum-based chemotherapy
To determine HRD status 2 separate tests will be performed in the study
1 Giscar assay developed by the sponsor
2 myChoice assay
If one or two tests identifies a HRD status
a PARP inhibitor treatment may be initiated according to current recommendations
To determine HRD status 2 separate tests will be performed in the study
1 Giscar assay developed by the sponsor
2 myChoice assay
If one or two tests identifies a HRD status
a PARP inhibitor treatment may be initiated according to current recommendations
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None